Clinical Trials
Sale
Colorectal Cancer Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class Monoclonal Antibody, Peptides, Polymer, Small Molecule, Gene Therapy; Product Type; By Treatment Type: Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others Drug Profile; Key Players
According to American Cancer Society stats, colorectal cancer is the leading cause of cancer-associated mortality in males, and it is a common cause of death for females under 50 years of age. It is estimated that approximately 150,000 United States individuals will be diagnosed with colorectal cancer in 2024. Hence, several drugs by leading companies in the healthcare industry are currently in the pipeline, intended to provide immediate and effective solutions to those affected.
Key Takeaways
- Major companies involved in the non-small cell lung cancer (NSCLC) drugs market include Takeda Pharmaceuticals International AG, Eli Lilly and Company, Immatics Biotechnologies GmbH and Daiichi Sankyo Co., Ltd., among others.
- The U.S. FDA and EMA play a vital role in the drug pipeline for colorectal cancer as they offer breakthrough designations and fast-track approvals for accelerating access to new and effective treatment alternatives to patients.
- Leading drugs currently under the drug pipeline include Tisotumab Vedotin, A2B530 and Tucatinib among others.
Report Coverage
The Colorectal Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights on the colorectal cancer drugs currently undergoing clinical trials. It covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on colorectal cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to colorectal cancer are covered.
Colorectal Cancer Drug Pipeline Outlook
Colorectal cancer is a cancer type affecting the colon (large intestine) or rectum. Changes in bowel movements, leading to constipation or diarrhea, blood in stool, sudden weight loss, prolonged gas pains, bloating and cramps are amongst common disease symptoms. It is diagnosed through digital rectal exams, fecal occult blood tests, and physical exams such as sigmoidoscopy, colonoscopy, or stool tests.
Colorectal cancer treatment may vary based on the cancer stage and the patient’s overall health and preferences. Surgical procedures such as polypectomy, local excision, colon resection with anastomosis or colostomy can be advised to a patient, Neoadjuvant therapies include radiation or chemotherapy. In March 2024, the United States FDA approved Fruzaqla (fruquintinib), an anti-VEGF treatment-based targeted therapy for metastatic colorectal cancer. The drug works by blocking the blood supply to a tumor and is advised to individuals with prior chemotherapy and a different anti-VEGF treatment.
In June 2024, the US FDA granted accelerated approval to Bristol Myer Squibb’s KRAZATI ® (adagrasib). The drug is intended to be used as a targeted treatment for KRASG12C -mutated locally advanced or metastatic colorectal cancer.
The U.S. FDA also approved an oral chemotherapy drug LONSURF (trifluridine and tipiracil) to be used in combination with Avastin (bevacizumab). While LONSURF was originally approved in 2015 and Avastin received its approval in 2004, the combination of these two together inhibited cancer spreading. LONSURF prevents cancer cell replication whereas Avastin blocks blood supply to the tumor. Such approvals demonstrate a preference for using combination drugs in order to provide maximum efficacy to patients. Moreover, the regulatory landscape for colorectal cancer drugs is also shifting towards a positive note as more drugs get swift approvals from the authorities.
The Colorectal Cancer Pipeline Report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
Colorectal Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of colorectal cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analysis based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analysis based on the route of administration.
- Oral
- Parenteral
- Others
Colorectal Cancer – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total clinical trials conducted, with approximately 2,400 plus drugs in the pipeline.
Colorectal Cancer– Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under Colorectal Cancer pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.
Colorectal Cancer Clinical Trials Assessment – Competitive Dynamics
The EMR report for the colorectal cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:
- Takeda Pharmaceuticals International AG
- Eli Lilly and Company
- Immatics Biotechnologies GmbH
- Daiichi Sankyo Co., Ltd.
- Millennium Pharmaceuticals, Inc.
- Pfizer & Co., Inc.
- Bristol-Myers Squibb Company
Colorectal Cancer – Pipeline Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of colorectal cancer clinical trial drugs.
Tisotumab Vedotin - Seagen Inc.
Sponsored by Seagen Inc., Tisotumab Vedotin is being evaluated for its efficacy, safety, and tolerability for the treatment of several solid tumors including colorectal center. Currently, in an open-label phase 2 study, the drug evaluation is expected to be completed by November 2026.
Tucatinib With Trastuzumab and TAS-102 - Academic and Community Cancer Research United
Combined with trastuzumab and TAS-102, tucatinib is in the phase 2 trial to investigate its efficacy against shrinking tumors in patients with HER2-positive colorectal cancer. It belongs to a kinase inhibitor drug class.
A2B530 - A2 Biotherapeutics Inc.
A2B530 is a Tmod™ CAR T cell therapy being evaluated in EVEREST-1, a multi-centre, open-label study including adult subjects with recurrent unresectable, locally advanced, or metastatic colorectal cancer. The first phase of the trial emphasizes determining the safety and optimal dosage whereas phase 2 further evaluates the safety and efficacy of the drug.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Treatment Type |
|
| Leading Sponsors Covered |
|
Key Questions Answered in the Colorectal Cancer – Pipeline Assessment Report
- What is the current landscape of colorectal cancer pipeline drugs?
- How many companies are developing colorectal cancer drugs?
- How many phase III and phase IV drugs are currently present in colorectal cancer pipeline drugs?
- Which companies/institutions are leading the colorectal cancer drug development?
- What is the efficacy and safety profiles of colorectal cancer pipeline drugs?
- What are the opportunities and challenges present in the Colorectal Cancer drug pipeline landscape?
- Which company is conducting major trials for colorectal cancer drugs?
- What are the geographies covered for clinical trials in colorectal cancer?
- What are emerging trends in colorectal cancer clinical trials?
Related Reports
Colorectal Cancer Therapeutics Market
Pancreatic Cancer Drug Pipeline
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Colorectal Cancer
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Colorectal Cancer
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Colorectal Cancer: Epidemiology Snapshot
5.1 Colorectal Cancer Incidence by Key Markets
5.2 Colorectal Cancer– Patients Seeking Treatment in Key Markets
6 Colorectal Cancer: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Colorectal Cancer: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Colorectal Cancer, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Colorectal Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Colorectal Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 AMT2003
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 mFOLFOX6
10.2.3 BBI608
10.2.4 Arfolitixorin
10.2.5 Other Drug
11 Colorectal Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Niraparib
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 AMT2003
11.2.3 Cetuximab
11.2.4 JX-594
11.2.5 Other Drugs
12 Colorectal Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 MGD007
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 HRO761
12.2.3 Nivolumab
12.2.4 Other Drugs
13 Colorectal Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 αPD1-MSLN-CAR T cells
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 BTG-002814
13.2.3 IM96 CAR-T cells
13.2.4 Nilotinib
13.2.5 Other Drugs
14 Colorectal Cancer, Key Drug Pipeline Companies
14.1 Takeda Pharmaceuticals International AG
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Eli Lilly and Company
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Immatics Biotechnologies GmbH
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Daiichi Sankyo Co., Ltd.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Millennium Pharmaceuticals, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Pfizer & Co., Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Bristol-Myers Squibb Company
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER